Overview

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

Status:
Terminated
Trial end date:
2017-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Nivolumab